The Latest “Buzz on the Street” Show: Featuring AREV Brands International (CSE: AREV) (OTC: AREVF) Genotyping Technology

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “AREV International Brands Ltd. Becomes World’s First Cannabis Company to Utilize New Genotyping Technology.”

AREV Brands International Ltd. (CSE: AREV) (OTC: AREVF), is pleased to announce that it has contributed DNA samples from select BC Bud Depot genovarsTM to the inaugural batch run on the world’s first BeadArray genotype chip to be designed specifically for the cannabis genome. The Illumina Infinium HTS microarray, designed and wholly owned by Lighthouse Genomics Inc., allows up to 96 samples to be economically tested in a single batch run. Through its holding BC Bud Depot, AREV has entered into a Letter of Intent to undertake genetic quality screening of all BC Bud Depot strains and genovarsTM. This advancement in genomics technology provides BC Bud Depot access to what is now the world’s most efficient and cost-effective method of gathering quality, targeted data from the cannabis genome.

AREV Brands International Ltd. produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.

As the cannabis market continues to expand around the globe, research has confirmed that cannabidiol products are growing in popularity as well. Cowen & Co. analysts noted that nearly 7% of Americans are already using CBD-based product, clarifying that most consumers are using CBD as a supplement. Primarily, legal CBD is derived from the hemp plant, which falls under the cannabis family, while marijuana-derived CBD must comply with seed-to-sale state laws, which makes it illegal to transport products across state lines. However, hemp-derived CBD products are perfectly legal throughout almost every U.S. state as CBD is generally more accepted when compared to THC as it does not provide consumers with psychoactive effects. Despite the biological difference between THC and CBD, the two compounds are linked to providing similar therapeutic benefits. Clinical trials and research have suggested that CBD can suppress consumers’ illnesses or symptoms associated with cancer, anxiety, chronic pain, and depression. Moreover, clinical trials have led to the U.S. Food and Drug Administration’s approval of Epidiolex to treat two forms of childhood epilepsy. As a result, Cowen projects that CBD users will grow to 10% of U.S. adults or 25 million consumers by 2025. Consumers in the U.S. can easily find CBD products at their local stores and even pharmacies now. The growth of the CBD marketplace also compliments the THC marketplace, fueling recreational cannabis sales as well. The U.S. dominates the cannabis market as it accounts for the majority of the global share due to its early adoption. Furthermore, in combination with Canada’s recent legalization, the North American region is already positioned to witness exponential growth. According to data compiled by IMARC Group, the North American legal cannabis market was valued at USD 8 Billion in 2017. By 2023, the market is projected to reach USD 35 Billion while registering a CAGR of 28% from 2018 to 2023.

Despite the impact CBD has made throughout the U.S., regulators are still maintaining strict control of the plant. For instance, earlier in 2019, New York City health officials ordered bakeries and restaurants to stop adding CBD to their beverages and food, while Maine and Ohio have curbed CBD sales. However, the FDA recently held a hearing to receive public feedback and opinion about CBD regulations. Under current FDA regulations, it is illegal to add CBD into food supplies or market it as a dietary supplement. However, FDA Commissioner Scott Gottlieb said he is open to hearing positive, large-scale data and research regarding the efficacy and safety of the compound. Cowen also noted that the majority of consumers between the ages of 18 to 34 are using liquid extracts, which accounted for 44% of the market, followed by topicals at 26%, capsules at 22% and beverages at 19%. “It’s critical that we address these unanswered questions about CBD and other cannabis and cannabis-derived products to help inform the FDA’s regulatory oversight of these products,” Gottlieb said. “Especially as the agency considers whether it could be appropriate to exercise its authority to allow the use of CBD in dietary supplements and other foods.”

For more information, please visit: AREV Brands International Ltd.

For more corporate news on AREV Brands International Ltd., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

3 Comments
  1. Ross Gerber 1 month ago
    Reply

    scientists and researchers finally begin to unravel the tangled & convoluted codes of cannabis genotypes

    • Mark Mandell 1 month ago
      Reply

      finding a way to specifically raise genetic strains to treat specific ailments will be the future for cannabis genetics

      • Farid Sleem 3 weeks ago
        Reply

        cannabis helps with pain, improving patient’s quality of life, reducing opioid use, and opening up a path to create personalized treatments to replace the opioid dependency

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For arev brands international ltd. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.